Artgen Biotech PJSC (MOEX:ISKJ)
Russia
· Delayed Price · Currency is RUB 59.54
+0.84 (1.43%)
At close: Jul 8, 2022
Artgen Biotech PJSC Income Statement
Financials in millions RUB. Fiscal year is January - December.
Millions RUB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1,521 | 1,369 | 1,137 | 1,181 | 1,084 | Upgrade
|
Revenue Growth (YoY) | 11.18% | 20.38% | -3.72% | 8.93% | 29.73% | Upgrade
|
Cost of Revenue | 1,221 | 402.4 | 457.14 | 461.39 | 388.69 | Upgrade
|
Gross Profit | 300.84 | 966.15 | 679.77 | 719.4 | 695.33 | Upgrade
|
Selling, General & Admin | - | 602.72 | 504.82 | 496.52 | 410.94 | Upgrade
|
Other Operating Expenses | - | 15.8 | 14.58 | 11.19 | 11.54 | Upgrade
|
Operating Expenses | - | 689.41 | 572.88 | 588.98 | 497.37 | Upgrade
|
Operating Income | 300.84 | 276.74 | 106.89 | 130.42 | 197.97 | Upgrade
|
Interest Expense | -95.06 | -49.23 | -67.81 | -50.68 | -40.16 | Upgrade
|
Interest & Investment Income | 75.42 | 32.33 | 12.48 | 6.23 | 3.96 | Upgrade
|
Earnings From Equity Investments | -3.5 | -24.17 | 23.14 | -5.21 | -0.37 | Upgrade
|
Currency Exchange Gain (Loss) | -5.38 | 2.02 | -3.36 | -1.24 | -0.83 | Upgrade
|
Other Non Operating Income (Expenses) | -54.89 | -15.44 | -9.1 | -33.11 | -50.83 | Upgrade
|
EBT Excluding Unusual Items | 217.43 | 222.24 | 62.24 | 46.42 | 109.74 | Upgrade
|
Gain (Loss) on Sale of Investments | - | -1.4 | - | - | 30.86 | Upgrade
|
Gain (Loss) on Sale of Assets | - | -1.34 | -20.63 | -1.69 | 0.92 | Upgrade
|
Asset Writedown | - | - | -5.52 | -9.28 | -45.27 | Upgrade
|
Other Unusual Items | - | -8.11 | -6.79 | -5.98 | -2.77 | Upgrade
|
Pretax Income | 217.43 | 211.39 | 29.31 | 29.46 | 93.47 | Upgrade
|
Income Tax Expense | -23.74 | 16.74 | 6.23 | -4.09 | -9.93 | Upgrade
|
Earnings From Continuing Operations | 241.16 | 194.66 | 23.08 | 33.55 | 103.4 | Upgrade
|
Minority Interest in Earnings | -26.25 | -25.8 | 23.04 | -21.92 | -30.55 | Upgrade
|
Net Income | 214.91 | 168.86 | 46.12 | 11.63 | 72.85 | Upgrade
|
Net Income to Common | 214.91 | 168.86 | 46.12 | 11.63 | 72.85 | Upgrade
|
Net Income Growth | 27.27% | 266.14% | 296.51% | -84.04% | -13.84% | Upgrade
|
Shares Outstanding (Basic) | 93 | 93 | 87 | 80 | 75 | Upgrade
|
Shares Outstanding (Diluted) | 93 | 93 | 87 | 80 | 75 | Upgrade
|
Shares Change (YoY) | -0.01% | 6.60% | 8.64% | 6.67% | - | Upgrade
|
EPS (Basic) | 2.32 | 1.82 | 0.53 | 0.15 | 0.97 | Upgrade
|
EPS (Diluted) | 2.32 | 1.82 | 0.53 | 0.15 | 0.97 | Upgrade
|
EPS Growth | 27.47% | 243.40% | 264.54% | -85.01% | -13.96% | Upgrade
|
Free Cash Flow | 382.16 | 230.56 | 84.37 | 127.51 | -31.74 | Upgrade
|
Free Cash Flow Per Share | 4.13 | 2.49 | 0.97 | 1.59 | -0.42 | Upgrade
|
Dividend Per Share | - | 1.200 | 1.000 | - | - | Upgrade
|
Dividend Growth | - | 20.00% | - | - | - | Upgrade
|
Gross Margin | 19.77% | 70.60% | 59.79% | 60.92% | 64.14% | Upgrade
|
Operating Margin | 19.77% | 20.22% | 9.40% | 11.04% | 18.26% | Upgrade
|
Profit Margin | 14.12% | 12.34% | 4.06% | 0.98% | 6.72% | Upgrade
|
Free Cash Flow Margin | 25.12% | 16.85% | 7.42% | 10.80% | -2.93% | Upgrade
|
EBITDA | 385.55 | 325.9 | 146.93 | 188.79 | 250.84 | Upgrade
|
EBITDA Margin | 25.34% | 23.81% | 12.92% | 15.99% | 23.14% | Upgrade
|
D&A For EBITDA | 84.71 | 49.16 | 40.05 | 58.37 | 52.88 | Upgrade
|
EBIT | 300.84 | 276.74 | 106.89 | 130.42 | 197.97 | Upgrade
|
EBIT Margin | 19.77% | 20.22% | 9.40% | 11.04% | 18.26% | Upgrade
|
Effective Tax Rate | - | 7.92% | 21.26% | - | - | Upgrade
|
Revenue as Reported | 1,521 | 1,369 | 1,137 | 1,181 | 1,084 | Upgrade
|
Advertising Expenses | - | 106.33 | 72.46 | 61.87 | 43.87 | Upgrade
|
Updated Sep 5, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.